Phase II Pilot Study of Extracorporeal Phototherapy for Epidermolysis Bullosa Acquisita

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00004359

Enrollment

Registered

1999-10-19

Start date

1996-02-29

Completion date

Unknown

Last updated

2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epidermolysis Bullosa Acquisita

Keywords

dermatologic disorders, epidermolysis bullosa, genetic diseases and dysmorphic syndromes, rare disease

Brief summary

OBJECTIVES: I. Evaluate immunomodulation with extracorporeal photochemotherapy (ECP) in patients with epidermolysis bullosa acquisita. II. Investigate the effect of ECP on lymphocyte activity.

Detailed description

PROTOCOL OUTLINE: Oral methoxsalen (8-MOP) is administered 90 minutes prior to leukapheresis. Blood mononuclear cells are exposed to ultraviolet A light for 3 hours, then returned to the patient. The process is repeated on 2 successive days. Patients are re-treated every 3 to 4 weeks for a total of 6 treatments or until the skin has cleared.

Interventions

DRUGmethoxsalen

Study design

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Active epidermolysis bullosa acquisita

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026